Quarterly ResultMay 8, 2026, 04:13 PM
Integrated BioPharma Q3 Net Loss $(837)K; Sales Down 27.5%
AI Summary
Integrated BioPharma Inc. reported a significant decline in its financial performance for the three months ended March 31, 2026, with net sales decreasing by 27.5% to $10.1 million and a net loss of $(837) thousand, compared to a net income of $611 thousand in the prior year. The company also experienced a gross loss and operating loss for the quarter. Despite the losses, cash increased to $5.8 million, and net cash from operating activities for the nine months improved. The company highlighted risks from major customer concentration and negative impacts on margins from inflation and tariffs.
Key Highlights
- Net sales for Q3 2026 decreased 27.5% to $10.1 million from $13.9 million in Q3 2025.
- Company reported a net loss of $(837) thousand in Q3 2026, compared to net income of $611 thousand in Q3 2025.
- Basic net loss per common share was $(0.03) in Q3 2026, down from $0.02 income in Q3 2025.
- Gross profit turned into a loss of $(276) thousand in Q3 2026, from a profit of $1.55 million in Q3 2025.
- Cash balance increased to $5.83 million as of March 31, 2026, up from $3.62 million on June 30, 2025.
- Net cash provided by operating activities for the nine months ended March 31, 2026, was $2.44 million, up 65.2% YoY.
- Approximately 90% of consolidated net sales in Q3 2026 were derived from two major customers.
- PNC Bank Loan Agreement expiration date extended to July 14, 2026.